The recent publication of randomized controlled trials and long-term follow-up data enabled researchers to re-examine transoral incisionless fundoplication (TIF) and its role in treating patients with chronic GERD. The review of these randomized controlled trials demonstrated the ability of TIF to eradicate GERD symptoms, heal esophagitis, and improve distal esophageal acid exposure in carefully chosen patient populations. The studies also established TIF’s superiority to conventional medical therapy, particularly in clinical scenarios in which proton-pump inhibitors do not lead to complete resolution of symptoms across the spectrum of classic and atypical GERD manifestations, such as regurgitation and laryngopharyngeal reflux. Long-term data show continued positive outcomes and durability up to 6 years after the procedure. Furthermore, these results were attained with a low rate of serious adverse events, and generally without resulting in dysphagia, gas bloat, or flatulence.